Physician profile
Ching Lin
NPI 1447889183
$637.91
in general payments reported to CMS, 2019-2025
12 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.53 · 2024: $195 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.92 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $145.00 | 2025 | |
| Abbvie INC. | $99.99 | 2025 | Venclexta |
| Incyte Corporation | $83.98 | 2024-2025 | Monjuvi, Zynyz, Jakafi |
| Emd Serono, INC. | $66.41 | 2024 | |
| Merck Sharp & Dohme LLC | $57.82 | 2024-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $35.33 | 2023 | |
| Celgene Corporation | $30.40 | 2025 | Reblozyl |
| Daiichi Sankyo INC. | $29.20 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $28.70 | 2024 | |
| Genentech USA, INC. | $26.21 | 2024 | Phesgo, Tecentriq Hybreza, Itovebi |
| Deciphera Pharmaceuticals INC. | $17.61 | 2025 | Romvimza, Qinlock |
| Astrazeneca Pharmaceuticals LP | $17.26 | 2024 | Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ching Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.